No Picture
Los Angeles Biotech News

Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update

TORRANCE, Calif., March 31, 2023 /PRNewswire/ — Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported its results of operation for the year ended Decem… […]

No Picture
Los Angeles Biotech News

Soylent Boosts Nationwide Accessibility, Expands Partnership with Meijer to Offer Plant-Based Nutrition Shakes in 260 Midwest Stores

LOS ANGELES, March 31, 2023 /PRNewswire/ — Soylent, maker of award winning nutrition shakes, with a mission to make complete, sustainable nutrition accessible, appealing and affordable to all, today announced an expanded partnership with Meijer Grocer… […]

No Picture
Los Angeles Biotech News

$1.5 million CIRM grant funds UCLA research to advance stem cell-based technologies for treating intellectual disability syndromes (UCLA Broad Stem Cell Research Center)

The post $1.5 million CIRM grant funds UCLA research to advance stem cell-based technologies for treating intellectual disability syndromes (UCLA Broad Stem Cell Research Center) appeared first on Life Sciences.
[…]

No Picture
Los Angeles Biotech News

Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2022 Financial Results and Business Highlights

DAVIS, Calif.–(BUSINESS WIRE)–Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the fourth quarter and full year of 2022. … […]

No Picture
Los Angeles Biotech News

When it comes to identifying new gene therapies, she’s in it for the long run (UCLA Broad Stem Cell Research Center)

The post When it comes to identifying new gene therapies, she’s in it for the long run (UCLA Broad Stem Cell Research Center) appeared first on Life Sciences.
[…]

No Picture
Los Angeles Biotech News

FDA lifts partial clinical hold on Vigil Neuroscience’s TREM2 antibody, removing dosing cap

When Vigil Neuroscience filed its IPO papers in late 2021, the biotech revealed that the FDA had just cleared its Phase I trial — but with a partial clinical hold that limited dosing to under a certain level. More than a year later, the FDA has […]